Revolo Biotherapeutics

Revolo Biotherapeutics is a private, venture-funded biotechnology company pioneering an upstream, disease-agnostic approach to treating immune-mediated conditions. Its core technology involves peptide-based therapies that simultaneously upregulate regulatory T/B cells and downregulate effector T cells, aiming for rapid, prolonged effect without systemic immune suppression. The lead candidate '1104 has completed a Phase 2 trial in eosinophilic esophagitis (EoE), with plans for a larger Phase 2 trial in 2025, while '1805 is being prepared for Phase 2 trials in rheumatoid arthritis and ulcerative colitis. The company's strategy includes exploring convenient subcutaneous and sublingual administration routes to potentially disrupt the current treatment landscape.

Peptide-based therapies designed to restore immune homeostasis via dual action: upregulating T/B regulatory cells and downregulating effector T cells, without broad immune suppression. Platform is disease-agnostic and offers potential for subcutaneous and sublingual administration.

Revolo operates in the crowded and competitive fields of autoimmunity and allergy, competing against large pharma biologics, JAK inhibitors, and other novel immune-modulators. Its differentiation hinges on proving its unique mechanism offers superior long-term remission without immunosuppression and more convenient administration compared to current standards.